Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20995891 | 1.00 | CHRM2 (0.53) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7926060 | 0.94 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7926056 | 0.94 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7920287 | 0.94 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL16672047 | 0.92 | CHRM2 (0.47) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL941667 | 0.89 | CHRM2 (0.50) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7678513 | 0.87 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL7678515 | 0.87 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL16221684 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM4CHRM3KMT2A | |
| SCHEMBL19962806 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM4CHRM3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2012040167-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088583-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | CHRM2 4875/4885CHRM1 4852/4885CHRM4 4830/4885 |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | PREP, PRSS1, PEPD | CHRM2 4875/4885CHRM1 4852/4885CHRM4 4830/4885 |
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | CHRM2 4875/4885CHRM1 4852/4885CHRM4 4830/4885 |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | CHRM2 4875/4885CHRM1 4852/4885CHRM4 4830/4885 |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | CHRM2 4875/4885CHRM1 4852/4885CHRM4 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.